Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.

PURPOSE To identify predictive factors for a good leukapheresis yield and to determine peripheral-blood progenitor cell (PBPC) dose requirements for rapid hematopoietic engraftment. PATIENTS AND METHODS Seventy-one patients with germ cell cancer (GCC) underwent PBPC harvest for autologous transplantation following high-dose therapy. Aphereses were performed after chemotherapy during granulocyte colony-stimulating factor (G-CSF) administration. RESULTS A median of two aphereses (range, two to five) resulted in 4.6 x 10(8) mononuclear cells (MNC)/kg, 15.7 x 10(4) colony-stimulating units granulocyte-macrophage (CFU-GM)/kg, and 6.0 x 10(6) CD34+ cells/kg. Peripheral blood MNC count correlated significantly with number of harvested CD34+ cells per kilogram (r = .49; P < .0001) and with CFU-GM count per kilogram (r = .35; P < .002). Circulating CD34+ cells from peripheral blood gave the best correlations to collected CD34+ cells per kilogram (r = .92; P < .0001), as well as to harvested CFU-GM per kilogram (r = .48; P < .0001). A preleukapheresis number of CD34+ cells greater than 4 x 10(4)/mL was highly predictive for a PBPC collection yield that contained more than 2.5 x 10(6) CD34+ cells/kg harvested by a single leukapheresis. After autologous transplantation, 41 patients were assessable for hematopoietic engraftment. They engrafted in a median time of 9 days (range, 7 to 18) to a WBC count greater than 1.0 x 10(9)/L, 10 days (range, 7 to 18) to an absolute neutrophil count (ANC) greater than 0.5 x 10(9)/L, and 11 days (range, 7 to 62) to a platelet (PLT) count greater than 20 x 10(9)/L. Good correlations were seen between reinfused CD34+ cell count and recovery of WBC count, ANC, and PLT count, with r values of .65 (P < .001), .65 (P < .001), and .45 (P < .03), respectively. Patients reinfused with a PBPC dose greater than 2.5 x 10(6) CD34+ cells/kg recovered hematopoiesis in a significantly shorter time than patients who received less than 2.5 x 10(6) CD34+ cells/kg. CONCLUSION Rapid hematopoietic engraftment can be achieved by a PBPC dose of greater than 2.5 x 10(6) CD34+ cells/kg. When circulating preleukapheresis CD34+ cell counts are greater than 4 x 10(4)/mL, a PBPC autograft that contains more than 2.5 x 10(6) CD34+ cells/kg can be collected by a single leukapheresis.

[1]  A. Khwaja,et al.  Development of a simplified single-apheresis approach for peripheral-blood progenitor-cell transplantation in previously treated patients with lymphoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Storb,et al.  Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantation , 1994, British journal of haematology.

[3]  H. Goldschmidt,et al.  Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. , 1994, Blood.

[4]  L. Kanz,et al.  Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comments] , 1994 .

[5]  J. Armitage,et al.  High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft , 1994 .

[6]  J. Radford,et al.  Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis , 1993 .

[7]  N. Davidson,et al.  Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. , 1993, Blood.

[8]  F. Appelbaum,et al.  Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor , 1993 .

[9]  L. Schwartzberg,et al.  Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. , 1993, Bone marrow transplantation.

[10]  H. Goldschmidt,et al.  Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. , 1993, Experimental hematology.

[11]  G. Demetri,et al.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.

[12]  G. Kandel,et al.  Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. , 1992, Bone marrow transplantation.

[13]  J. Armitage,et al.  The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. , 1991, Blood.

[14]  L. To,et al.  Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. , 1990, Experimental hematology.

[15]  A. Ho,et al.  Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Experimental hematology.

[16]  D. Weisenburger,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. , 1989, Blood.

[17]  P. Höcker,et al.  Myeloid progenitor cells (CFU-GM) predict engraftment kinetics in autologous transplantation in children. , 1989, Bone marrow transplantation.

[18]  L. To,et al.  Circulating autologous stem cells collected in very early remission from acute non‐lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy , 1985, British journal of haematology.

[19]  A. Fauser,et al.  Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood , 1978 .

[20]  A. Hirao,et al.  Effects of progenitor cell dose and preleukapheresis use of human recombinant granulocyte colony-stimulating factor on the recovery of hematopoiesis after blood stem cell autografting in children. , 1993, Experimental hematology.

[21]  Effects of recombinant human granulocyte colonystimulating factor on hemopoietic cells in cancer patients , 1988 .